申请人:Sumitomo Pharmaceuticals Co., Ltd.
公开号:US20040209939A1
公开(公告)日:2004-10-21
Pyrrole derivatives represented by the following formula:
1
wherein Ring Z is an optionally substituted pyrrole ring, etc.; W
2
is —CO—, —SO
2
—, an optionally substituted C
1
-C
4
alkylene, etc.; Ar
2
is an optionally substituted aryl, etc.; W
1
and Ar
1
mean the following (1) and (2): (1) W
1
is an optionally substituted C
1
-C
4
alkylene, etc.; Ar
1
is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W
1
is an optionally substituted C
2
-C
5
alkylene, an optionally substituted C
2
-C
5
alkenylene, etc.; and Ar
1
is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W
1
, or a pharmaceutically acceptable salt thereof. These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.
以下公式所表示的吡咯衍生物:1其中,环Z是可选取代的吡咯环等;W2是—CO—、—SO2—、可选取代的C1-C4烷基等;Ar2是可选取代的芳基等;W1和Ar1分别表示以下(1)和(2):(1)W1是可选取代的C1-C4烷基等;Ar1是具有1至4个氮原子作为环形成原子的可选取代的双环杂芳基;(2)W1是可选取代的C2-C5烷基、可选取代的C2-C5烯基等;Ar1是取代了羧基、烷氧基羰基等的芳基或单环杂芳基,其在W1的结合位置的邻位或间位取代。或其药学上可接受的盐。这些化合物可用作药物,例如用于器官或组织的纤维化抑制剂。